Absci Corp (ABSI)vsRoyalty Pharma Plc (RPRX)
ABSI
Absci Corp
$9.18
-2.96%
HEALTHCARE · Cap: $1.34B
RPRX
Royalty Pharma Plc
$58.60
+0.47%
HEALTHCARE · Cap: $33.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 138026% more annual revenue ($2.54B vs $1.84M). RPRX leads profitability with a 32.0% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 53/100 (C-).
ABSI
Avoid20
out of 100
Grade: F
RPRX
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ABSI.
Margin of Safety
-60.9%
Fair Value
$36.41
Current Price
$58.60
$22.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 32 of every $100 in revenue as profit
16.5% revenue growth
Generating 1.4B in free cash flow
Areas to Watch
Trading at 8.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 46.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABSI
The strongest argument for ABSI centers on Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Revenue Growth, Free Cash Flow. Profitability is solid with margins at 32.0% and operating margin at 19.8%. Revenue growth of 16.5% demonstrates continued momentum.
Bear Case : ABSI
The primary concerns for ABSI are Price/Book, EPS Growth, Market Cap.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ABSI profiles as a value stock while RPRX is a growth play — different risk/reward profiles.
ABSI carries more volatility with a beta of 2.42 — expect wider price swings.
RPRX is growing revenue faster at 16.5% — sustainability is the question.
RPRX generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (53/100 vs 20/100), backed by strong 32.0% margins and 16.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Absci Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?